Clinical Trial Update: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated whether adding elotuzumab to bortezomib and dexamethasone improves outcomes in relapsed or refractory multiple myeloma; the study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Empliciti (elotuzumab)
• Velcade (bortezomib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2016-01-26